The situation in the case of AD is worse; the current anti-AD drugs, acetylcholinesterase inhibitors, and N-methyl-D-aspartate receptor (NMDAR) modulators are of little anti-symptomatic efficacy and do not prevent disease progression (Gauthier et al., 2016; Szeto and Lewis, 2016). This evidence concerns the gene ACHE and Alzheimer disease.